[Skip to Navigation]
Medical News & Perspectives
June 23, 2021

Semaglutide’s Success Could Usher in a “New Dawn” for Obesity Treatment

JAMA. 2021;326(2):121-123. doi:10.1001/jama.2021.10307
Audio Clinical Review (43:35)
1x
0:00 / 0:00
JAMA Medical News Audio (26:18)
1x
0:00 / 0:00

Over the long, checkered history of weight-loss drugs, a safe and highly effective medication has been the elusive holy grail. The handful of drugs currently approved for long-term treatment of obesity have a good safety profile and help people lose an average of about 5% to 10% of their body weight—a clinically meaningful amount but far from the results seen with bariatric surgery, the gold standard. That’s why, when weight-loss results for the drug semaglutide started to come in, “we all said, ‘Wow—game changing,’” Robert Kushner, MD, recalled in a recent interview with JAMA.

×